当前位置: 首页 >> 检索结果
81. Assessing Daily Life Physical Activity by Actigraphy in Pulmonary Arterial Hypertension: Insights From the Randomized Controlled Study With Selexipag (TRACE).
作者: Luke S Howard.;Stephan Rosenkranz.;Robert P Frantz.;Anna R Hemnes.;Thomas Pfister.;Shu-Fang Hsu Schmitz.;Hall Skåra.;Marc Humbert.;Ioana R Preston.
来源: Chest. 2023年163卷2期407-418页
Reduced daily life physical activity (DLPA) in pulmonary arterial hypertension (PAH) contributes to a poor quality of life.
82. A 30-Minute Spontaneous Breathing Trial Misses Many Children Who Go On to Fail a 120-Minute Spontaneous Breathing Trial.
作者: Kelby E Knox.;Justin C Hotz.;Christopher J L Newth.;Michael C K Khoo.;Robinder G Khemani.
来源: Chest. 2023年163卷1期115-127页
The optimal length of spontaneous breathing trials (SBTs) in children is unknown.
83. Long-term Azithromycin in Children With Bronchiectasis Unrelated to Cystic Fibrosis: Treatment Effects Over Time.
作者: Don Vicendese.;Stephanie Yerkovich.;Keith Grimwood.;Patricia C Valery.;Catherine A Byrnes.;Peter S Morris.;Shyamali C Dharmage.;Anne B Chang.
来源: Chest. 2023年163卷1期52-63页
Following evidence from randomized controlled trials, patients with bronchiectasis unrelated to cystic fibrosis receive long-term azithromycin to reduce acute respiratory exacerbations. However, the period when azithromycin is effective and which patients are likely to most benefit remain unknown.
84. Multimodal Telemonitoring for Weight Reduction in Patients With Sleep Apnea: A Randomized Controlled Trial.
作者: Kimihiko Murase.;Takuma Minami.;Satoshi Hamada.;David Gozal.;Naomi Takahashi.;Yoshinari Nakatsuka.;Hirofumi Takeyama.;Kiminobu Tanizawa.;Daisuke Endo.;Toshiki Akahoshi.;Yasutaka Moritsuchi.;Toru Tsuda.;Yoshiro Toyama.;Motoharu Ohi.;Yasuhiro Tomita.;Koji Narui.;Naho Matsuyama.;Tetsuro Ohdaira.;Takatoshi Kasai.;Tomomasa Tsuboi.;Yasuhiro Gon.;Yoshihiro Yamashiro.;Shinichi Ando.;Hiroyuki Yoshimine.;Yoshifumi Takata.;Akiomi Yoshihisa.;Koichiro Tatsumi.;Shin-Ichi Momomura.;Tomohiro Kuroda.;Satoshi Morita.;Takeo Nakayama.;Toyohiro Hirai.;Kazuo Chin.
来源: Chest. 2022年162卷6期1373-1383页
Telemonitoring the use of CPAP devices and remote feedback on device data effectively optimizes CPAP adherence in patients with OSA.
85. Effectiveness of a Long-term Home-Based Exercise Training Program in Patients With COPD After Pulmonary Rehabilitation: A Multicenter Randomized Controlled Trial.
作者: Anja Frei.;Thomas Radtke.;Kaba Dalla Lana.;Patrick Brun.;Thomas Sigrist.;Marc Spielmanns.;Swantje Beyer.;Thomas F Riegler.;Gilbert Büsching.;Sabine Spielmanns.;Ramona Kunz.;Tamara Cerini.;Julia Braun.;Yuki Tomonaga.;Miquel Serra-Burriel.;Ashley Polhemus.;Milo A Puhan.
来源: Chest. 2022年162卷6期1277-1286页
Most patients with COPD do not maintain exercise training after pulmonary rehabilitation (PR).
86. Immediate, Remote Smoking Cessation Intervention in Participants Undergoing a Targeted Lung Health Check: Quit Smoking Lung Health Intervention Trial, a Randomized Controlled Trial.
作者: Parris J Williams.;Keir E J Philip.;Navjot Kaur Gill.;Deirdre Flannery.;Sara Buttery.;Emily C Bartlett.;Anand Devaraj.;Samuel V Kemp.;Jamie Addis.;Jane Derbyshire.;Michelle Chen.;Katie Morris.;Anthony A Laverty.;Nicholas S Hopkinson.
来源: Chest. 2023年163卷2期455-463页
Lung cancer screening programs provide an opportunity to support people who smoke to quit, but the most appropriate model for delivery remains to be determined. Immediate face-to-face smoking cessation support for people undergoing screening can increase quit rates, but it is not known whether remote delivery of immediate smoking cessation counselling and pharmacotherapy in this context also is effective.
87. A Double-Blind Randomized Placebo-Controlled Phase 3 Trial of Tobramycin Inhalation Solution in Adults With Bronchiectasis With Pseudomonas aeruginosa Infection.
作者: Wei-Jie Guan.;Jin-Fu Xu.;Hong Luo.;Xing-Xiang Xu.;Yuan-Lin Song.;Wan-Li Ma.;Zong-An Liang.;Xue-Dong Liu.;Guo-Jun Zhang.;Xiao-Ju Zhang.;Rong-Kai Li.;Shu-Yang Zhu.;Yi-Jie Zhang.;Xing-Jun Cai.;Li-Ping Wei.;Dong-Bo Tian.;Hui Zhao.;Ping-Yan Chen.;Jie-Ming Qu.;Nan-Shan Zhong.; .
来源: Chest. 2023年163卷1期64-76页
Few large-scale studies have demonstrated the efficacy of tobramycin nebulization in bronchiectasis. We evaluated the efficacy and safety of nebulized tobramycin inhalation solution (TIS) in adults with bronchiectasis with Pseudomonas aeruginosa infection.
88. Ventilatory Strategy to Prevent Atelectasis During Bronchoscopy Under General Anesthesia: A Multicenter Randomized Controlled Trial (Ventilatory Strategy to Prevent Atelectasis -VESPA- Trial).
作者: Moiz Salahuddin.;Mona Sarkiss.;Ala-Eddin S Sagar.;Ioannis Vlahos.;Christopher H Chang.;Archan Shah.;Bruce F Sabath.;Julie Lin.;Juhee Song.;Teresa Moon.;Peter H Norman.;George A Eapen.;Horiana B Grosu.;David E Ost.;Carlos A Jimenez.;Gouthami Chintalapani.;Roberto F Casal.
来源: Chest. 2022年162卷6期1393-1401页
Atelectasis negatively influences peripheral bronchoscopy, increasing CT scan-body divergence, obscuring targets, and creating false-positive radial-probe endobronchial ultrasound (RP-EBUS) images.
89. Neutralizing COVID-19 Convalescent Plasma in Adults Hospitalized With COVID-19: A Blinded, Randomized, Placebo-Controlled Trial.
作者: Wesley H Self.;Allison P Wheeler.;Thomas G Stewart.;Harry Schrager.;Jason Mallada.;Christopher B Thomas.;Vince D Cataldo.;Hollis R O'Neal.;Nathan I Shapiro.;Conor Higgins.;Adit A Ginde.;Lakshmi Chauhan.;Nicholas J Johnson.;Daniel J Henning.;Stuti J Jaiswal.;Manoj J Mammen.;Estelle S Harris.;Sonal R Pannu.;Maryrose Laguio-Vila.;Wissam El Atrouni.;Marjolein de Wit.;Daanish Hoda.;Claudia S Cohn.;Carla McWilliams.;Carl Shanholtz.;Alan E Jones.;Jay S Raval.;Simon Mucha.;Tina S Ipe.;Xian Qiao.;Stephen J Schrantz.;Aarthi Shenoy.;Richard D Fremont.;Eric J Brady.;Robert H Carnahan.;James D Chappell.;James E Crowe.;Mark R Denison.;Pavlo Gilchuk.;Laura J Stevens.;Rachel E Sutton.;Isaac Thomsen.;Sandra M Yoder.;Amanda J Bistran-Hall.;Jonathan D Casey.;Christopher J Lindsell.;Li Wang.;Jill M Pulley.;Jillian P Rhoads.;Gordon R Bernard.;Todd W Rice.; .
来源: Chest. 2022年162卷5期982-994页
Convalescent plasma has been one of the most common treatments for COVID-19, but most clinical trial data to date have not supported its efficacy.
90. A Trial of Intranasal Corticosteroids to Treat Childhood OSA Syndrome.
作者: Ignacio E Tapia.;Justine Shults.;Christopher M Cielo.;Andrea B Kelly.;Lisa M Elden.;Jonathan M Spergel.;Ruth M Bradford.;Mary Anne Cornaglia.;Laura M Sterni.;Jerilynn Radcliffe.
来源: Chest. 2022年162卷4期899-919页
Intranasal corticosteroids (INCS) are frequently used to treat OSA syndrome (OSAS) in children. However, their efficacy has not been rigorously tested.
91. Smartphone-Guided Self-prone Positioning vs Usual Care in Nonintubated Hospital Ward Patients With COVID-19: A Pragmatic Randomized Clinical Trial.
作者: Garrett Rampon.;Shijing Jia.;Ritwick Agrawal.;Nicholas Arnold.;Alejandro Martín-Quirόs.;Ernest A Fischer.;James Malatack.;Nikhil Jagan.;Amen Sergew.;Amy Hajari Case.;Kristin Miller.;Maged Tanios.;Gheorghe Doros.;Craig S Ross.;Michael A Garcia.;Kari R Gillmeyer.;Nicholas G Griffiths.;Badr Jandali.;Katherine L Modzelewski.;Justin M Rucci.;Steven Q Simpson.;Allan J Walkey.;Nicholas A Bosch.
来源: Chest. 2022年162卷4期782-791页
Safe, effective, and easily implementable treatments that reduce the progression of respiratory failure in COVID-19 are urgently needed. Despite the increased adoption of prone positioning during the pandemic, the effectiveness of this technique on progression of respiratory failure among nonintubated patients is unclear.
92. Neurovascular Dysregulation and Acute Exercise Intolerance in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: A Randomized, Placebo-Controlled Trial of Pyridostigmine.
作者: Phillip Joseph.;Rosa Pari.;Sarah Miller.;Arabella Warren.;Mary Catherine Stovall.;Johanna Squires.;Chia-Jung Chang.;Wenzhong Xiao.;Aaron B Waxman.;David M Systrom.
来源: Chest. 2022年162卷5期1116-1126页
Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) is characterized by intractable fatigue, postexertional malaise, and orthostatic intolerance, but its pathophysiology is poorly understood. Pharmacologic cholinergic stimulation was used to test the hypothesis that neurovascular dysregulation underlies exercise intolerance in ME/CFS.
93. Defibrotide Therapy for SARS-CoV-2 ARDS.
作者: David Frame.;Gianni B Scappaticci.;Thomas M Braun.;Mary Maliarik.;Thomas H Sisson.;Steven W Pipe.;Daniel A Lawrence.;Paul G Richardson.;Michael Holinstat.;Robert C Hyzy.;Daniel R Kaul.;Kevin S Gregg.;Vibha N Lama.;Gregory A Yanik.
来源: Chest. 2022年162卷2期346-355页
SARS-CoV-2-related ARDS is associated with endothelial dysfunction and profound dysregulation of the thrombotic-fibrinolytic pathway. Defibrotide is a polyanionic compound with fibrinolytic, antithrombotic, and antiinflammatory properties.
94. Optimizing COPD Acute Care Patient Outcomes Using a Standardized Transition Bundle and Care Coordinator: A Randomized Clinical Trial.
作者: Chantal E Atwood.;Mohit Bhutani.;Maria B Ospina.;Brian H Rowe.;Richard Leigh.;Lesly Deuchar.;Peter Faris.;Marta Michas.;Kelly J Mrklas.;Jim Graham.;Raymond Aceron.;Ron Damant.;Lee Green.;Naushad Hirani.;Kelly Longard.;Virginia Meyer.;Patrick Mitchell.;Willis Tsai.;Brandie Walker.;Michael K Stickland.
来源: Chest. 2022年162卷2期321-330页
Acute exacerbations of COPD (AECOPD) are associated with high morbidity and mortality and frequent readmissions.
95. Targeted Temperature Management After In-Hospital Cardiac Arrest: An Ancillary Analysis of Targeted Temperature Management for Cardiac Arrest With Nonshockable Rhythm Trial Data.
作者: Alexiane Blanc.;Gwenhael Colin.;Alain Cariou.;Hamid Merdji.;Guillaume Grillet.;Patrick Girardie.;Elisabeth Coupez.;Pierre-François Dequin.;Thierry Boulain.;Jean-Pierre Frat.;Pierre Asfar.;Nicolas Pichon.;Mickael Landais.;Gaëtan Plantefeve.;Jean-Pierre Quenot.;Jean-Charles Chakarian.;Michel Sirodot.;Stéphane Legriel.;Nicolas Massart.;Didier Thevenin.;Arnaud Desachy.;Arnaud Delahaye.;Vlad Botoc.;Sylvie Vimeux.;Frederic Martino.;Jean Reignier.;F S Taccone.;J B Lascarrou.
来源: Chest. 2022年162卷2期356-366页
Targeted temperature management (TTM) currently is the only treatment with demonstrated efficacy in attenuating the harmful effects on the brain of ischemia-reperfusion injury after cardiac arrest. However, whether TTM is beneficial in the subset of patients with in-hospital cardiac arrest (IHCA) remains unclear.
96. Asthma Control, Airway Mucus, and 129Xe MRI Ventilation After a Single Benralizumab Dose.
作者: Marrissa J McIntosh.;Harkiran K Kooner.;Rachel L Eddy.;Samira Jeimy.;Christopher Licskai.;Constance A Mackenzie.;Sarah Svenningsen.;Parameswaran Nair.;Cory Yamashita.;Grace Parraga.
来源: Chest. 2022年162卷3期520-533页
Patients with eosinophilic asthma often report poor symptomatic control and quality of life. Anti-IL-5 therapy, including anti-IL-5Rα (benralizumab), rapidly depletes eosinophils in the blood and airways and also reduces asthma exacerbations and improves quality of life scores. In patients with severe asthma, eosinophilic inflammation-driven airway mucus occlusions have been measured using thoracic x-ray CT imaging. Pulmonary 129Xe MRI ventilation defect percentage (VDP) also sensitively measures asthma airway dysfunction caused by airway hyperresponsiveness, remodeling, and luminal mucus occlusions. Using 129Xe MRI and CT imaging together, it is feasible to measure both airway luminal occlusions and airway ventilation in relationship to anti-IL-5 therapy to ascertain the direct impact of therapy-induced eosinophil depletion on airway function.
97. Results of a Phase 2b Trial With GB001, a Prostaglandin D2 Receptor 2 Antagonist, in Moderate to Severe Eosinophilic Asthma.
作者: Mark H Moss.;Njira L Lugogo.;Mario Castro.;Nicola A Hanania.;Andrea Ludwig-Sengpiel.;Dinesh Saralaya.;Rafal Dobek.;Iñigo Ojanguren.;Ivan Vyshnyvetskyy.;Jean-Marie Bruey.;Robin Osterhout.;Cindy-Ann Tompkins.;Karen Dittrich.;Kartik Raghupathi.;Hector Ortega.; .
来源: Chest. 2022年162卷2期297-308页
Prostaglandin D2 receptor 2 (DP2) antagonists inhibit prostaglandin D2-induced effects, including recruitment and activation of cells driving asthma pathogenesis. However, challenges identifying target population and end points persist.
98. Dupilumab Reduces Oral Corticosteroid Use in Patients With Corticosteroid-Dependent Severe Asthma: An Analysis of the Phase 3, Open-Label Extension TRAVERSE Trial.
作者: Lawrence D Sher.;Michael E Wechsler.;Klaus F Rabe.;Jorge F Maspero.;Nadia Daizadeh.;Xuezhou Mao.;Benjamin Ortiz.;Leda P Mannent.;Elizabeth Laws.;Marcella Ruddy.;Nami Pandit-Abid.;Juby A Jacob-Nara.;Rebecca Gall.;Paul J Rowe.;Yamo Deniz.;David J Lederer.;Megan Hardin.
来源: Chest. 2022年162卷1期46-55页
Many patients with severe asthma require chronic corticosteroid treatment to maintain asthma control.
99. Azithromycin for Poorly Controlled Asthma in Children: A Randomized Controlled Trial.
作者: Jagat Jeevan Ghimire.;Kana Ram Jat.;Jhuma Sankar.;Rakesh Lodha.;Venkat K Iyer.;Hitender Gautam.;Seema Sood.;S K Kabra.
来源: Chest. 2022年161卷6期1456-1464页
Azithromycin has immunomodulatory actions, and its beneficial effects have been demonstrated in asthmatic adults. Data on children are limited.
100. Effects of CPAP on Metabolic Syndrome in Patients With OSA: A Randomized Trial.
作者: Sara Q C Giampá.;Sofia F Furlan.;Lunara S Freitas.;Thiago A Macedo.;Adriana Lebkuchen.;Karina H M Cardozo.;Valdemir M Carvalho.;Franco C Martins.;Indira F B Azam.;Valéria Costa-Hong.;Heno F Lopes.;Mariana L Baptista.;Carlos E Rochitte.;Luiz A Bortolotto.;Geraldo Lorenzi-Filho.;Luciano F Drager.
来源: Chest. 2022年161卷5期1370-1381页
OSA is associated with metabolic syndrome (MS), but it is unclear whether OSA treatment with CPAP can revert MS.
|